Upgrade to SI Premium - Free Trial

Merck (MRK) Says KEYTRUDA is the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma

July 26, 2018 6:54 AM
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA®, Merck’s anti-PD-1 therapy, has ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles